Profile data is unavailable for this security.
About the company
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
- Revenue in USD (TTM)7.05m
- Net income in USD-58.50m
- Incorporated2006
- Employees65.00
- LocationOcugen Inc11 GREAT VALLEY PARKWAYMALVERN 19355United StatesUSA
- Phone+1 (484) 328-4701
- Fax+1 (302) 655-5049
- Websitehttps://ocugen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 191.72m | -31.56m | 321.71m | 288.00 | -- | 6.51 | -- | 1.68 | -0.1742 | -0.1742 | 1.06 | 0.2671 | 0.9623 | 1.92 | 8.03 | 665,680.60 | -15.91 | -25.99 | -24.20 | -40.62 | 61.73 | 61.90 | -16.53 | -35.81 | 1.72 | -2.16 | 0.6287 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 323.32m | 1.60k | -- | 0.487 | -- | 0.2728 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 323.41m | 67.00 | -- | 1.67 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Agenus Inc | 161.42m | -239.61m | 324.65m | 389.00 | -- | -- | -- | 2.01 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 326.16m | 377.00 | -- | -- | -- | 1.90 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| OraSure Technologies, Inc. | 304.64m | 22.85m | 326.90m | 638.00 | 14.54 | 0.7669 | 7.63 | 1.07 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 330.77m | 862.00 | 57.38 | 1.18 | 15.58 | 0.7596 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 335.83m | 54.00 | -- | 3.01 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 344.45m | 100.00 | -- | 228.42 | -- | 38.65 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Aura Biosciences Inc | 0.00 | -78.65m | 363.15m | 88.00 | -- | 1.74 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 363.16m | 203.00 | -- | 0.6676 | -- | 2.04 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Ocugen Inc | 7.05m | -58.50m | 365.44m | 65.00 | -- | 12.08 | -- | 51.84 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 377.44m | 45.00 | -- | 3.33 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -81.19m | 385.76m | 94.00 | -- | 2.20 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 389.69m | 357.00 | -- | 1.87 | -- | 2.30 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 396.91m | 33.00 | -- | 3.35 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Ocugen Inc's reporting currency: US Dollar USD
10.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.91m | 4.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.70m | 1.44% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.21m | 1.25% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 2.61m | 1.01% |
| Millennium Management LLCas of 31 Mar 2024 | 1.93m | 0.75% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 1.20m | 0.47% |
| Two Sigma Investments LPas of 31 Mar 2024 | 1.03m | 0.40% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 956.73k | 0.37% |
| HRT Financial LLCas of 31 Mar 2024 | 806.50k | 0.31% |
| Group One Trading LPas of 31 Mar 2024 | 624.80k | 0.24% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
